Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05784688 · ClinicalTrials.gov registry record · Phase 1
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
A Phase 1 study of Colorectal Cancer and Solid Tumor, sponsored by TiumBio Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 11
- Study locations
NCT05784688: Recruiting Phase 1 study of Colorectal Cancer and Solid Tumor, sponsored by TiumBio Co..
NCT05784688 is a Phase 1 study of Colorectal Cancer and Solid Tumor that is actively recruiting participants, run by TiumBio Co.. The registered enrollment target is 140 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05784688, a Phase 1 study of Colorectal Cancer and Solid Tumor, is actively recruiting participants, sponsored by TiumBio Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
Primary Outcome
At least 1 Dose limiting toxicity (DLT) during Cycle1
Conditions Studied
Interventions
- DRUG TU2218 + KEYTRUDA® (Pembrolizumab)
Study Locations (11)
Other
- CHA University Bundang Medical Center - Seongnam
- Seoul National University Bundang Hospital - Seongnam
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital - Seoul
- The Catholic University of Korea Seoul St. Mary Hospital - Seoul
- The Catholic University of Korea St. Vincent's Hospital - Suwon
Texas
- NEXT Oncology - San Antonio
- Hope Cancer Center - Tyler
Washington
- Medical Oncology - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT05784688 shows while recruiting
NCT05784688 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which TU2218 + KEYTRUDA® (Pembrolizumab) is the first listed.
NCT05784688 lists 11 locations in 3 states (Other, Texas, Washington).
Frequently Asked Questions
What is clinical trial NCT05784688 about?
NCT05784688 is a clinical study titled "Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors". This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
What is the current status of trial NCT05784688?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-03-10. Estimated completion is 2028-12.
What conditions does trial NCT05784688 study?
This clinical trial studies the following conditions: Colorectal Cancer, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Biliary Tract Cancer.
What interventions are being tested in trial NCT05784688?
The interventions under investigation include: TU2218 + KEYTRUDA® (Pembrolizumab) (DRUG).
Who is sponsoring clinical trial NCT05784688?
This trial is sponsored by TiumBio Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05784688 being conducted?
This trial has 11 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05784688's enrollment target sits among peer trials
140 177th of 381 higher than 204 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI